Research Study Initiated
In September 2019, a research study regarding compound K9MGP was initiated. Two doses of the drug 0.1 milligrams/Kilogram and 0.3 mg/Kg were administered IM into a muscle located adjacent to the spinal column towards the hind limbs. Two different needle lengths, 5/8 and 1 inch, were employed as well as two different needle thicknesses, 27 and 23 gauge, were tested. The higher dose was also administered by IV. As anticipated, the high dose of K9MGP resulted in plasma levels three times higher than the lower dose. This indicated linearity of a dose-response relationship. There were no differences in the plasma levels associated with the two different needle lengths or gauges. The drug produced the highest plasma level when given IV.